| | | All patients (n = 294) | Deceased patients (n = 101) | Survivor patients (n = 193) | |
| | Age, mean (SD) (y) | 64.33 (16.38) | 66.77 (16.56) | 63.01 (16.21) | 0.064 |
| | Sex | | Male | 152 (51.71) | 66 (65.34) | 86 (44.55) | 0.001 | | Female | 142 (48.29) | 35 (34.66) | 107 (55.45) |
| | Coexisting conditions | | Hypertension | 159 (54.08) | 50 (49.50) | 109 (56.47) | 0.255 | | Diabetes | 80 (27.21) | 33 (32.67) | 47 (24.35) | 0.128 | | Malignancy | 16 (5.44) | 8 (7.92) | 8 (4.14) | 0.175 | | Cardiovascular disease | 61 (20.74) | 19 (18.81) | 42 (21.76) | 0.554 | | Chronic kidney disease | 16 (5.44) | 4 (3.96) | 12 (6.21) | 0.418 | | Respiratory disease | 20 (6.80) | 4 (3.96) | 16 (8.29) | 0.161 | | Heart disease | 196 (66.66) | 67 (66.33) | 129 (66.83) | 0.931 | | Heart failure | 61 (20.74) | 23 (22.77) | 38 (19.68) | 0.536 | | Critical illness | 187 (63.60) | 91 (90.09) | 96 (49.74) | <0.001 |
| | Interleukin-6 (pg/mL), median (IQR) | 92.4 (35, 233.5) | 120.4 (56.3, 260.2) | 75.8 (21.6, 175.1) | 0.020 |
| | Procalcitonin (ng/mL), median (IQR) | 3.7 (1.1, 14.5) | 5.5 (3.2, 18.9) | 1.4 (1.2, 3.8) | 0.003 |
| | White blood cell count (×109/L) | | 1600–11000 | 183 (62.25) | 62 (61.39) | 121 (62.69) | 0.826 | | 11001–48400 | 111 (37.75) | 39 (38.61) | 72 (37.30) |
| | C-reactive protein (mg/L) | | 0.5–10 | 37 (12.58) | 7 (6.94) | 30 (15.54) | 0.034 | | 10–116 | 257 (87.41) | 94 (93.06) | 163 (84.45) |
| | Fluid balance during hospitalization, mL, median (IQR) | −250 (−550, 240) | 150 (−100, 350) | −390 (−570, 100) | <0.001 |
| | Creatinine, mg/dL, median (IQR) | 2.6 (0.8, 4.1) | 2.2 (1.1, 4.2) | 2.4 (1.1, 4.1) | 0.053 |
| | Creatinine, mg/dL, median (IQR) | 2.4 (0.8, 3.8) | 2 (1, 4.2) | 2.2 (0.9, 4) | 0.032 |
| | Change of creatinine, mg/dL, median (IQR) | 0.2 (0.1, 0.3) | 0.2 (0.1, 0.28) | 0.2 (0.1, 0.3) | 0.943 |
|
|
